UNASSIGNED:探讨通过鼓室导管插入术(TAC)地塞米松治疗难治性梅尼埃病(MD)的长期疗效和安全性。
未经评估:在此回顾性分析中,从2020年1月至2020年8月在我院接受TAC治疗的60例单侧难治性MD患者随访2年。50例接受内淋巴囊减压(ESD)的患者和50例接受鼓室类固醇(ITS)的患者被确定为对照组。眩晕控制,听力水平,耳鸣,在研究期间评估了听觉丰满度和功能水平。
UNASSIGNED:经过2年随访,TAC治疗的难治性MD患者的有效眩晕控制率为76.7%(46/60),完全控制率为58.3%(35/60),实质性控制率为18.3%(11/60)。TAC的眩晕控制率与ESD相当(χ2=0.313,p>0.05),且显著高于ITS(χ2=4.380,p<0.05)。这些患者的听力损失率为10.8%(4/37),与对照组无显著差异(χ2=2.452,p>0.05)。TAC患者耳鸣改善率为56.7%(34/60),明显高于ESD(χ2=11.962,p<0.001)和ITS(χ2=15.278,p<0.001)。TAC组的听觉饱满度改善率为56.7%(34/60),显著高于ESD组(χ2=11.962,p<0.001)和ITS组(χ2=5.635,p<0.05)。TAC组功能水平改善率为71.7%(43/60),远高于ITS组(χ2=17.256,p<0.001),但TAC和ESD之间没有显着差异(χ2=0.410,p>0.05)。TAC治疗后无患者出现并发症或不良反应。
UNASSIGNED:通过TAC治疗地塞米松可有效控制眩晕发作并改善难治性MD患者的相关症状,为MD的治疗提供有价值的新见解。
UNASSIGNED: To explore the long-term efficacy and safety of dexamethasone treatment via tympanic antrum catheterization (TAC) in intractable Meniere\'s disease (MD).
UNASSIGNED: In this retrospective analysis, 60 unilateral intractable MD patients treated with TAC in our hospital from January 2020 to August 2020 were followed for 2 years. Fifty patients who underwent endolymphatic sac decompression (ESD) and 50 patients who accepted intratympanic steroids (ITS) were established as the control groups. Vertigo control, hearing level, tinnitus, aural fullness and functional level were assessed during the study.
UNASSIGNED: The effective vertigo control rate of intractable MD patients with TAC treatment was 76.7% (46/60) after 2 years follow-up, with a complete control rate of 58.3% (35/60) and a substantial control rate of 18.3% (11/60). The vertigo control rate of TAC was comparable to that of ESD (χ 2 = 0.313, p > 0.05), and significantly higher than that of ITS (χ 2 = 4.380, p < 0.05). The hearing loss rate of these patients was 10.8% (4/37), which was not significantly different from the control groups (χ 2 = 2.452, p > 0.05). The tinnitus improvement rate of patients with TAC was 56.7% (34/60), which was significantly higher than that of patients with ESD (χ 2 =11.962, p < 0.001) and ITS (χ 2 =15.278, p < 0.001). The aural fullness improvement rate in the TAC group was 56.7% (34/60), which was significantly higher than that in the ESD (χ 2 = 11.962, p < 0.001) and ITS groups (χ 2 = 5.635, p < 0.05). The functional level improvement rate in the TAC group was 71.7% (43/60), which was much higher than that in the ITS group (χ 2 = 17.256, p < 0.001), but there was no significant difference between TAC and ESD (χ 2 = 0.410, p > 0.05). No patients had complications or adverse reactions following TAC treatment.
UNASSIGNED: Dexamethasone treatment via TAC can effectively control vertigo attacks and improve related symptoms of intractable MD patients, providing valuable new insights into the treatment of MD.